NCT07043907View on ClinicalTrials.gov

PANK-003 Cell Injection Combined With Standard Adjuvant Chemotherapy After Surgery in Patients With Stage IIIA NSCLC

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

115

Participants

Timeline

Start Date

July 8, 2025

Primary Completion Date

July 8, 2028

Study Completion Date

June 18, 2029

Conditions

Stage IIIA Non-small Cell Lung Cancer

Interventions

DRUG

PANK-003 cell injection combined with standard postoperative adjuvant chemotherapy

PANK-003 cell injection combined with standard postoperative adjuvant chemotherapy

All Listed Sponsors

lead

Shenzhen Celconta Life Science Co., Ltd.

INDUSTRY